You searched for "diagnostic"
Intravesical instillation of chemotherapy before radical surgery for upper UTUC
Upper urinary tract urothelial carcinoma (UTUC) is a rare but increasingly prevalent form of urothelial cancer, accounting for 5–10% of cases, with an annual incidence of two to three cases per 100,000 individuals in Western Europe. Radical nephroureterectomy (RNU) with...FUJIFILM Healthcare Europe launches a dedicated prostate fusion imaging platform
FUJIFILM Healthcare Europe is pleased to have unveiled the ARIETTA™ 65 IntuitiveFusion.Sustainable healthcare: what steps can urologists take?
Human health is intrinsically linked to environmental health, making the ever-pressing climate crisis fundamentally a public health emergency. The healthcare sector is responsible for 8% of the UK’s greenhouse gas (GHG) emissions worldwide [1]. As the largest publicly funded healthcare...The microbial syndicate: dysbiosis and origins of recurrent UTIs
Traditional dogma held that urine was sterile. However, recent molecular studies have revealed an underground microbial community, known as the urinary microbiome or ‘urobiome’ [1]. Far from being harmful, this community of microorganisms helps modulate immune responses, regulate inflammation, and...Using change theories can help nurses implement better care in prostate cancer
Nurses can help support change in prostate cancer care by understanding change management and models and provide leadership in improving prostate cancer care. An important part of being able to lead change is to understand change theories such as the...PREDICT Prostate – individualised, evidence-based estimates of survival and treatment benefit
Earlier this year ‘PREDICT Prostate’ was launched online alongside a high-profile publication in PLOS Medicine. The prognostic model and decision-aid has been designed to inform treatment decision-making among men newly diagnosed with non-metastatic prostate cancer. David Thurtle and Vincent Gnanapragasam...Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...
Renal fossa recurrence after nephrectomy for renal cell carcinoma
This paper is an analysis of 36 years of radical nephrectomy for renal cell carcinoma in the Mayo Clinic (1970-2006). In particular, it contains an analysis of the risk of renal fossa recurrence after nephrectomy (partial nephrectomies are not included)...
Urethral sphincter function before and after radical prostatectomy
This paper from Holland will be useful for urologists involved in radical prostatectomy (RP) for cancer of the prostate. It presents a PubMed search between 1980 and 2012. Twenty-five out of 124 articles were further analysed, mainly English-language papers. Several...New charity launches to highlight urethral strictures – men’s silent epidemic
A new charity, the Collaboration for Urological Research and Education (CURE), has today called for urgent action to address one of Britain’s biggest silent epidemics – urethral strictures. Launching Stricture Awareness Month (SAM) in March, CURE has called on healthcare...
